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We examined binding to excitatory amino acid and inhibitory amino acid receptors in frozen hippocampal sections 
prepared from surgical specimens resected from 8 individuals with medically refractory temporal lobe epilepsy. The 
excitatory receptors studied included N-methyl-D-aspartate (NMDA), strychnine-insensitive glycine, phencyclidine, 
and quisqualate. The inhibitory receptors studied were gamma-aminobutyric acid type A (GABA,) and benzodiaze- 
pine. Excitatory and inhibitory amino acid receptor binding were differentially altered in the patients with temporal 
lobe epilepsy in comparison to 8 age-comparable autopsy control subjects, and changes in receptor binding were 
regionally selective in four areas. Binding to phencyclidine receptors associated with the NMDA channel was reduced 
by 35 to 70% in all regions in the hippocampi of the patients. In contrast, binding to the NMDA recognition site and 
its associated glycine modulatory site was elevated by 20 to 110% in the cornu ammonis (CA) 1 area and dentate gyrus 
of the hippocampus of the patients. Binding to these sites was unaffected in area CA4. Binding to the quisqualate-type 
excitatory amino acid receptor was unchanged in all regions except the stratum lacunosum moleculare CA1, where it 
was increased by 63%. GABA, and benzodiazepine receptor binding was reduced by 20 to 60% in CA1 and CA4, 
but unchanged in dentate gyrus. The data indicate that excitatory and inhibitory amino acid receptors are altered in 
the hippocampus of patients with temporal lobe epilepsy. 
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Considerable evidence suggests that abnormalities of 
specific neurotransmitter systems play a role in epi- 
lepsy. Impairment of gamma-aminobutyric acid(GABA) 
ergic inhibitory neurotransmission may contribute to 
epilepsy: GABA type A (GABAA) receptor antago- 
nists are potent convulsants and GABAergic markers 
are selectively reduced in temporal lobe epilepsy (TLE) 
11-81. Excitatory amino acid (EAA) neurotransmitters 
such as glutamate and aspartate also may contribute to 
epileptic seizures and to central nervous system (CNS) 
injury consequent to seizures 19-13]. EAA neuro- 
transmitters are the principal excitatory neurotransmit- 
ters in mammalian brain and participate prominently 
in normal hippocampal function 1141. EAA receptor 
agonists are also potent convulsants and neurotoxins 
113, 15-17}. Local injection of EAA receptor agonists 
and stimulation of glutamatergic afferent pathways pro- 
duce a pattern of acute and chronic morphological 
changes in the rat hippocampus that are similar to the 
changes found in the hippocampus of patients with 
TLE [17-251. EAA receptor antagonists possess anti- 
convulsant properties and prevent the morphological 
changes associated with seizures 113, 16,26-28}. EAA 
receptors may be involved in the formation of epilep- 
togenic foci since antagonists of EAA receptors sup- 
press the development of spontaneous seizures and as- 
sociated neurochemical changes produced by kindling, 
a model of TLE 129-331. Direct evidence to support 
the role of EAA in human epilepsy, however, is limited 
t34-373. 
The current study is based on the hypothesis that 
binding to EAA and inhibitory amino acid (IAA) neu- 
rotransmitter receptors may be altered in epileptic 
brain tissue of patients with TLE. We measured bind- 
ing to receptors associated with the N-methy1-D- 
aspartate (NMDA) receptodchannel complex, the 
quisqualate-type EAA receptors, and the GABAA- 
benzodiazepine complex IAA-type receptors in hippo- 
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Fig 1. Tbe receptor components that comprise the N M D A  receptor/ 
channel complex. The N M D A  recognition szte can be selectively 
labeled wzth [3Hjglutamate. Acttvatzon ofthe glycine modulatory 
szte markedly enhances receptorlchannel actzwation {'HjGlyctne 
can be wed t o  selectively label thzs site. The phencyclzdzne (PCP) 
analogues, trztzated tbzenyl derzvatzve of PCP (TCP) and 
MK-801, reduce receptorlchunnel acttuatzon by binding t o  u szte 
wzthin the channel The binding site can be labeled sehctively 
wzth {jH}TCP. 
campal tissue resected from patients with medically re- 
fractory TLE and from comparably aged postmortem 
control specimens. 
The regional distribution of EAA and 1AA receptors 
in brain can be imaged and studied quantitatively by 
labeling each receptor with a tritiated ligand under con- 
ditions selective for each receptor type. The NMDA- 
type EAA receptodchannel complex is comprised of 
several regulatory binding sites (Fig 1) [38}. The 
NMDA recognition site can be selectively labeled, un- 
der appropriate conditions, with E3H]glutamate. The 
associated glycine modulatory site can be measured 
with C3H]glycine. The tritiated thienyl derivative of 
phencyclidine (TCP) selectively labels a binding site 
located within the NMDA receptor-associated iono- 
phore. The quisqualate-subtype of EAA receptors 
can be measured with X3H]glutamate under selective 
conditions. The modulatory receptors comprising the 
GABA, receptor/ionophore complex can be mea- 
sured with [3H]muscimol to label the GABA, recogni- 
tion site and [3H}flunitrazepam to label the associated 
benzodiazepine site [3C)]. 
Materials and Methods 
We studied 8 patients (4  males and 4 females) with medically 
refractory TLE whose seizure focus orlginated unilaterally 
(Table 1). The anterior 2 cm of the hippocampus was re- 
sected from these patients. Control hippocampus was ob- 
tained at autopsy from 8 subjects (4 males and 4 females) 
who had no reported history of neurological or psychiatric 
disease (mean age ? standard error of mean, 46 f 5 years; 
postmortem delay, 11 +- 2 hours). Hippocampal tissue was 
examined by a neuropathologisr (P. E. M.) to determine an 
anatomical diagnosis, and neuronal loss was rated qualita- 
tively. 
Materials 
C3H}TCP was obtained from New England Nuclear (Wil- 
mington, DE). C3H]Glutamate, C3H]g1ycine, [3H]muscimol, 
and ['H]flunitrazepam were obtained from Amersham (Ar- 
lington Heights, IL). All the unlabeled compounds were 
purchased from commercial sources. 
Table 1 .  Clinical Charactmitics and Netlropathological Findings of Patients with Temporal Lobe Epilepsy 
Age at Duration of Seizure 
Seizure Initial Frequent Frequence Medications 
Patient Side Onset Febrile Seizures at Time of at Time of 
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Astrocytoma, grade 1 
Astrocytoma, grade 1 







Neuronal loss in den- 
tate gyrus 
CPS = complex partial seizures; GTC = generalized tonic-clonic seizures; SPS = simple partial seizures; PHT = phenytoin; P = primidone; 
CBZ = carbamaepine; VPA = valproic acid. 
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Tissue Preparation 
Once obtained, hippocampal specimens from patients with 
TLE and autopsy control subjects were quickly frozen on 
dry ice, stored at - 70°C, and mounted on cryostat chucks. 
Mounted specimens were allowed to equilibrate to the tem- 
perature of the cryostat ( -  12 to - 20°C) and 20-pm frozen 
sections were cut and thaw-mounted onto gelatin-coated 
slides. Binding to each type of receptor was carried out in 
adjacent serial sections from each specimen. Total receptor 
binding and nonspecific binding were determined in at least 
3 sections per specimen per each receptor assay In order to 
remove endogenous neurotransmitters and modulatory 1i- 
gands, all sections underwent a prewash for 30 minutes at 
4°C in the indicated buffer and were blown dry under a 
stream of air at room temperature prior to receptor labeling. 
The sections were incubated with radioactive ligands at sub- 
saturating concentrations for periods of time shown pre- 
viously to allow equilibrium conditions to be reached. During 
the incubation period, sections were placed in cytomaders 
containing the PH)ligand (final volume, 8 ml); under these 
conditions less than 5% of free ligand is bound. 
N M D A  Recognition Site Binding Assay 
The EAA receptor agonist [3H}glutamate was used to label 
the NMDA-type EAA receptor recognition site under condi- 
tions that select for binding to NMDA recognition sites [40, 
41). Sections were prewashed for 30 minutes at 4°C in 50 
mM Tris-acetate (pH 7.4) to remove endogenous EAA neu- 
rotransmitters, and were dried under a stream of air at room 
temperature. Subsequently, sections were incubated for 45 
minutes in 50 mM Tris-acetate (4"C, p H  7.4) containing 2.5 
pM quisqualate and 40 nM [3H]glutamate to label NMDA 
recognition sites selectively. Since glutamate binds to both 
NMDA and quisqualate receptors, a 2.5 pM concentration 
of quisqualate, which saturates quisqualate receptors, was in- 
cluded in the incubation buffer so that [3H]glutamate would 
selectively label the remaining NMDA-type EAA receptors. 
A second group of sections was incubated in the above buffer 
and unlabeled glutamate (1 mM) to determine the level of 
nonspecific binding. Following incubation, sections were 
rinsed three times with 2 ml of ice-cold buffer, followed by 
a final rinse with 2 ml of ice-cold glutaraldehyde (49%)- 
acetone mixture (1:19 vol/vol), and quickly dried under a 
stream of warm air to minimize uneven ligand dissociation. 
Glycine Modulatoly Site Binding Assay 
Tissue sections were prewashed in 50 mM Tris-citrate (pH 
7.4,4"C) for 30 minutes to remove endogenous ligands, and 
then were dried under a stream of au at room temperature. 
Tissue sections were then incubated in the same buffer (pH 
7.4) containing 100 nM [3H]glycine and 100 pM strychnine 
for 35 minutes at 4°C 142). Under these conditions, the satu- 
rating concentration of strychnine prevents [3H]glycine from 
labeling the inhibitory glycine receptor and provides a selec- 
tive measure of the glycine modulatory sites associated with 
the NMDA receptorlchannel complex 142). Nonspecific 
binding was determined in the same buffer in the presence 
of 1 mM unlabeled glycine and represented less than 10% 
of total binding. Following incubation, sections were rinsed 
three times with 2 ml of ice-cold buffer, followed by a final 
rinse with 2 ml of ice-cold glutaraldehyde-acetone mixture 
(1:19 vol/vol), and quickly dried under a warm stream of air 
to optimize the level of specific binding and to minimize 
uneven ligand dissociation. 
Phencyclidine Receptor (NMDA-Associated 
Channel Binding Site) Binding Assay 
Sections were prewashed for 30 minutes in 50 mM Tris- 
acetate (pH 7.4, 4°C) to remove endogenous modulatory 
compounds, and sections were dried under a stream of air 
at room temperature. Phencyclidine (PCP) receptors were 
labeled with the selective PCP receptor ligand ['HITCP. Tis- 
sue sections were incubated with 30 nM E3H]TCP in 50 mM 
Tris-acetate plus 1 mM magnesium (Md') acetate for 45 
minutes at 4°C (pH 7.4) 141, 431. Addition of 1 mM Mg2+ 
to the incubation buffer previously has been shown to max- 
imize the level of f3H)TCP binding in frozen bran sections 
1431. With this method, binding equilibrium is aLhieved by 
approximately 45 minutes in the presence of 1 mM Mg2+. 
The level of nonspecific binding was determined by incubat- 
ing sections in the same buffer containing 20 pM unlabeled 
TCP. The level of nonspecific binding was minimized by 
subsequently rinsing the sections, after the incubation, three 
times for 1 minute each with ice-cold buffer. Sections were 
then rapidly dried under a stream of warm air. 
Quispalate-Type Receptor Binding Assay 
Sections were prewashed for 30 minutes in 50 mM Tris- 
hydrochloric acid (HCl) (pH 7.4, 4°C) to remove endoge- 
nous ligands and then dried under a stream of cool air. The 
quisqualate subtype of EAA receptors was labeled with 
C3H)glutamate in the presence of a saturating concentration 
of NMDA to prevent [3H)glutamate binding to the NMDA 
site. This method selectively labels quisqualate receptors in 
human brain tissue {40,44]. Tissue sections were incubated 
for 45 minutes in 50 mM Tris-HC1 (pH 7.4) containing 100 
p M  NMDA and 2.5 mM calcium chloride (CaCl,) at 4°C. 
Addition of 2.5 mM CaCI, to the incubation medium selec- 
tively maximizes binding to the quisqualate subtype of EAA 
receptors. The level of nonspecific binding was determined 
by incubating additional sections in the same incubation 
buffer plus 1 mM unlabeled glutamate. Subsequently, tissue 
sections were rinsed three times with 2 ml of ice-cold buffer 
and one time with ice-cold glutaraldehyde-acetone solution 
(1:19 vol/vol) and rapidly dried under a stream of warm air. 
Under these conditions, binding in this assay represents 
mainly postsynaptic neuronal, non-NMDA-type quisqualate 
receptors {44). In contrast to binding in membranes, quisqua- 
late receptor binding in the presence of CaCI, in frozen tissue 
sections represents postsynaptic high-affinity neuronal bind- 
ing sites rather than sequestration sites 1441. 
G A B A  Receptor Binding Assay 
Tissue sections were prewashed for 30 minutes in 50 mM 
Tris-citrate (pH 7.0,4"C) to remove endogenous ligands and 
were dried under a stream of cool air. GABAA receptors 
were labeled with the selective GABAA receptor ligand 
[3H]muscimol [45]. Sections were incubated for 30 minutes 
in 50 mM Tris-citrate (pH 7.0, 4°C) containing 50 nM 
[3H]muscimol. The level of nonspecific binding was deter- 
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mined in the presence of 100 pM GABA. Following incuba- 
tion, sections were rinsed four times with 2 ml of ice-cold 
buffer and rapidly dried under a stream of warm air. 
Benzodiazepine Receptor Binding Assay 
Sections were prewashed three times for 5 minutes each at 
4°C in 50 mM Tris-citrate (pH 7.0) to remove endogenous 
ligands and dried under a stream of cool air. Benzodiazepine 
receptors associated with GABA, receptor/channel com- 
plexes were labeled with the selective benzodiazepine recep- 
tor ligand {3H}flunitrazepam [46, 473. Sections were incu- 
bated for 30 minutes in 50 mM Tris-citrate (pH 7.0, 4°C) 
plus 10 nM [3H)flunitrazepam. Nonspecific binding was de- 
termined in the presence of the benzodiazepine receptor li- 
gand clonazepam (1 mM). Following incubation, sections 
were rinsed two times for 5 minutes each in ice-cold buffer 
and rapidly dried with a stream of warm air. 
Data Collection and Analysis 
Tissue sections were apposed to tritium-sensitive film (LKB 
Ultrafilm 3H; Pharmacia Co, Bromma, Sweden) for 1 to 8 
weeks. A set of radioactive standards (American Radiochemi- 
cals, St Louis, MO; ARC 3H) calibrated against brain pastes 
with known amounts of tritium was exposed with each film. 
Quantitanve analysis of the resulting autoradiograms was per- 
formed densitometrically with a microcomputer-based video 
densitometer system (Imaging Research, St Catharines, On- 
tario, Canada) {45}. Optical density values were converted 
to pmol/mg of protein values with a computer-generated 
polynomial regression analysis that compared film densities 
produced by the tissue sections to those of radioactive stan- 
dards. Ten readings per area were averaged and means of 
averaged readings from 3 to 5 sections per patient per recep- 
tor assay were compared to corresponding values for control 
subjects. Four hippocampal regions were examined: stratum 
lacunosum moleculare and stratum pyramidale of cornu am- 
monis 1 (CAl), area CA4 (hilus), and stratum moleculare of 
the dentate gyrus. Other hippocampal areas were not consis- 
tently present in resected tissue from patients with TLE. Re- 
ceptor binding data represent specific binding (total minus 
nonspecific binding) and are presented as mean * SEM in 
density units (fmol/mg of protein). Statistical comparisons 
were made with one-way analysis of variance (ANOVA). 
Results 
Table 1 contains a summary of the clinical characteris- 
tics and neuropathological findings of the 8 patients 
with TLE. The mean age (2 SEM) of the patients with 
TLE at the time of surgery was 32 2 5 years compared 
to 46 2 5 years for the autopsy control subjects (n = 
8). The range of ages in both groups was simiiar (TLE, 
18 to 60 years; controls, 22 to 61 years). Four of the 
8 patients with TLE were male. In 6 of the 8 patients 
with TLE, seizures originated from the left hemisphere. 
The initial age of onset of seizures occurred in the first 
postnatal year in 4 of the 8 patients with TLE and these 
seizures were all associated with febrile convulsions. 
The duration of the seizure disorder ranged from 6 to 
40 years (mean ? SEM, 21 ? 4 years). The patients 
with TLE were taking single or multiple anticonvulsant 
drugs (see Table 1). At the time of surgery, the patients 
received multiple different medications, including thia- 
mylal (Surital), fentanyl, droperidol, and labetalol, as 
well as the anesthetics nitrous oxide, isoflurane (For- 
ane). One patient received morphine, and another, lor- 
azepam. Although hippocampal neuronal loss was not 
examined quantitatively in this study, qualitative analy- 
sis of the hippocampi in the patients with TLE by a 
neuropathologist (P. E. M.) revealed mild astroglial 
proliferation and loss of pyramidal and granule cells in 
the majority of patients. Severe cell loss in the hippo- 
campal subfields and in the hilus, typical of Ammon’s 
horn sclerosis, was not evident in any of the patients. 
Three patients had extrahippocampal temporal lobe tu- 
mors: 2, grade 1 astrocytomas; and 1, oligodendro- 
glioma. 
NMDA Recognition Site Binding 
Regionally selective increases in binding to the NMDA 
recognition site were observed in the surgical hippo- 
campal specimens compared to autopsy control brains 
(Table 2, Figs 2 and 3). Significant mean increases in 
NMDA recognition site binding were found in stratum 
lacunosum moleculare and stratum pyramidale of hip- 
pocampal area CA1, and in stratum moleculare of the 
dentate gyms but not in the CA4 subfield of the hippo- 
campi of patients with TLE, compared to autopsy con- 
trol subjects. Elevated levels of NMDA recognition 
site binding were not found in all TLE specimens: 1 
TLE specimen exhibited levels of NMDA receptor 
binding lower than the mean level in autopsy control 
subjects. The interspecimen variability in receptor 
binding was greater in the TLE group than in the au- 
topsy control subjects. 
Glycine Modalatory Site Binding 
Selective laminar changes in E3Hfglycine binding were 
observed in the CA1 hippocampal subfield (see Table 
2 and Fig 3 ) .  In the TLE group, glycine modulatory 
site binding was significantly increased in stratum lacu- 
nosum moleculare but the level of binding in stratum 
pyramidale was equivalent to the level in autopsy con- 
trol subjects. Binding in stratum moleculare in the den- 
tate gyrus of TLE specimens was significantly elevated 
relative to binding in autopsy control subjects. In con- 
trast, equivalent binding densities were observed in 
hippocampal subfield CA4 of TLE and control groups. 
The variation in {3H)glycine binding in both TLE and 
autopsy groups was greater than for any of the other 
binding assays and the degree of variation in the TLE 
group was especially pronounced. In fact, { ’Hfglycine 
binding densities in several patients with TLE were 
below the corresponding mean binding densities of the 
autopsy control subjects. 
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Table 2. Excitatov and Inhibitov Amino Acid Receptor Binding in Hippocampas ~f Pcctients with Temporal Lobe Epilepsy (TLE)" 
Hippocampal Region 
Stratum Lacunosum Stratum Pyramidale of Stratum Moleculare 



















175 * 15 
365 ? 4gb 
(+ 108%) 
4 6 9 k  45 
801 f 137' 
(+71%) 
122 t 18 
79 f 10 
( -  35%) 
298 ? 25 
486 t 81' 
(+ 63%) 
3250 ? 281 
1803 f 279b 
(-45%) 
966 2 92 
790 * 93 
( -  18%) 
480 i 46 
702 t 84' 
(+46%) 
1093 t 72 
1231 * 186 
(+ 13%) 
373 i 27 
209 2 25" 
(-44%) 
487 * 29 
598 * 89 
(+23%h) 
4843 * 357 
3180 * 382' 
(-34%) 
1161 k 68 
820 k 87' 
( - 29%) 
96 * 13 
145 * 5 1  
(+51%)  
304 * 33 
344 2 95 
(+ 13%) 
112 f 10 
33 * 7d 
(-71%) 
201 * 16 
174 k 49 
( -  14%) 
1279 t 122 
53.1 2 183b 
( -  58%) 
480 f 45 
262 f 77' 
( -  4 5 % )  
288 rt 43 
610 ? 71d 
(+ 11 1%) 
675 t 67 
1065 t 162' 
(+ 57%) 
247 -C 29 
163 * 23' 
( -  34%) 
520 rt 40 
589 rt 72 
(+ 13%) 
4603 2 350 
3933 431 
( -  15%) 
1197 k 40 
1107 * 86 
( -  7%) 
aValues represent mean 2 SEM (fmol houndimg of protein). Values in parentheses represent percent change in mean receptor binding in 
hippocampus of patients with TLE relative to control subjects. 
' p  < 0.05. 
bp < 0.01. 
d$ < 0.001. 
Phencyclidine Receptor (Chunnel Site) Binding 
E3H}TCP binding to the NMDA-associated ionophore 
was consistently decreased in all four hippocampal re- 
gions of specimens from patients with TJX, compared 
with autopsy control values (see Table 2, Figs 2 and 
3). The largest decrease was observed in the CA4 sub- 
field, with smaller decreases in other hippocampal 
regions. Variation in PCP receptor binding between 
specimens was equivalent for TLE and autopsy control 
groups and was the smallest observed among the differ- 
ent binding assays. PCP binding densities were uni- 
formly lower in specimens from patients with TLE than 
corresponding mean densities of the autopsy control 
group. 
Compurison of Relative Changes in NMDA, Glycine, 
and Phencyclidine Receptor Binding 
Figure 4 illustrates the relative changes in binding to 
three components of the NMDA receptor/channel 
complex within individual patients with TIE. In stra- 
tum lacunosum moleculare of CA1, the pattern of rela- 
tive changes in NMDA, glycine, and PCP receptor 
binding was consistent between patients with TLE. The 
elevations of NMDA binding paralleled the changes in 
glycine receptor binding in patients with TLE. PCP 
receptor binding was consistently reduced in patients 
with TLE. Similar relative changes were observed in 
the other hippocampal areas examined. 
Quisquulute-Type Receptor Binding 
E3H1Glutamate binding to quisqualate-preferring re- 
ceptors in stratum lacunosum moleculare of CA1 was 
significantly elevated in patients with TLE, compared 
with autopsy specimens (see Table 2 and Fig 3). A 
similar trend was observed in stratum pyramidale of 
CA1, but the results were not statistically significant. 
However, equivalent binding densities were observed 
between specimens from patients with TLE and au- 
topsy control subjects in the CA4 subfield and in stra- 
tum moleculare of the dentate gyrus. Interspecimen 
variation in binding densities was greatest in the TLE 
group, compared with the autopsy group. 
GABAA Receptm Binding 
The changes in IAA receptor binding in the hippocam- 
pus of patients with TLE were different from those in 
EAA binding (Figs 5 and 6; see Table 2). GABA, re- 
ceptor binding was significantly reduced in both lami- 
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Fig 2. Quantitative autoradiograms of N M D A  (A, B )  andphen- 
cyclidine (PCP) (C, 0) receptor binding in the hippocampus of 
patients with temporal lobe epilepsy (TLE) (A, Ci and control 
subjects (B, 0). N M D A  receptors were labeled with 40 nM 
{3H)glutamate in 50 mM Tris-acetate plus 2.5 fli quisquaiate. 
PCP receptors were labeled with 40 n M  f3H)TCP (tritiated thi- 
enylderivative of PCP) in 50 mM Tris-acetate and 1 m M  magne- 
siam acetate. Note that the color scale bars for N M D A  and PCP 
receptor binding are different. N M D A  and PCP receptor binding 
have similar regional distributions in control .specimens. 
Fig 5 .  Quantitative autoradiograms of GABA, receptor binding 
in the h+pocampns of patients with temporal lobe epilepsy (TLE) 
(A) and autopsy controls (Bj. GABA,  receptors were labeled with 
50 nM {3H)muscimol in 50 mM Tris-citrate. 
S Mol. CA1 Subbeld S. Pyr. CA1 Subfield 
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Fig  3. Histograms of excitatory amino acid receptor binding. (At 
Stratum lacunosum moleculare of CAI,  (B) stratum pyramidale 
of CAI,  (C/ CA4, and (D) stratum moleculare in the dentate 
gyrus of' hippocampi from patients with chronic temporal lobe 
epilepsy (TLE) and from age-matched autopsy control subjectJ. 
Binding t o  quisqualate-type glutamate receptors (QUIS) and t o  
three receptors comprising the N M D A  receptor channel complex 
( N M D A  recognition site, &cine modulatoly site, and phencycli- 
dine [PCP] receptor) was measured in  adjacent frozen sections 
with in vitro receptor autoradiography. Data represent binding 
- ̂ ^  densities in hippocampal regions from individual patients. Hori- 
( <  iJ - NMDA Recogn bcn S te 
GI cine Recepror JP Receptor zontal lines indicute the mean values far each group. Hippocampi 
from 8 patients with TLE and from 8 autopsy control subjects 
< 0.001, TLE eersus control, one-way ANOVA. 












nae of the CA1 subfield and in the CA4 subfield 
in the hippocampus of patients with TIE, compared 
with autopsy control subjects. Binding densities, how- m b I G G  ever, were equivalent between the groups in the stra- 
turn moleculare of the dentate gyrus. The degree of 
GABA, receptor binding variability between speci- 
mens was similar for both TLE and autopsy control 
groups. 
al U 
1 2 3 4  5 6 7  
Benzodiazepine Receptor Binding TLE Patient 
The regional changes in benzodiazepine receptor bind- 
ing between and autopsy groups Paralleled the 
regional changes in GABAA receptor binding (see Ta- 
ble 2, and Figs 5 and 6); however, there was a nonsig- 
nificant trend for the magnitude of these changes to be 
smaller. [3H)Flunitrazepam binding to benzodiazepine 
Fig  4. Comparison relative binding t o  N M D A ,  glycine, and 
phencyclidine (PCP) receptors within temporal lobe epilepfy (TLE) 
specimens. Mean receptor binding in  stratum moleculare in CAI 
is expressedas a percent of mean binding in autopsjl controls. The 
patient numbers correspond to  the patient numbers listed in 
Table 1. 
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Fig  6. Histogram of  inhibitory amino acid (IAA) receptor bind- 
ing (GABA, and benzodiazepine [BDZ] receptors) in four hippo- 
campal regions from patients with temporal lobe epilepsy (TLE) 
and from age-mtched autopsy controls (n = 7igroup). IAA recep- 
tors were Labeled in sections adjacent to those used to  label excitatory 
amino acid receptors [see F i g  3). Data points represent binding 
densities in individual patients and horizontal lines indicate 
mean binding densitiesigroup. (A) Stratum lacunosum moleculare 
of C A I .  (Bi Stratum pyramidale of C A I .  (0 CA4. (D} Stratum 
moleculare of the dentate gyrus. *p < 0.05, ** p < 0.01, *+*p 
< 0.001. 
receptors was significantly reduced in stratum pyrami- 
dale of CA1 ( - 29%) with a similar trend in stratum 
lacunosum moleculare of CA1. Binding densities were 
similar between groups in stratum moleculare of the 
dentate gyrus. A significant decrease in binding was 
observed in TLE CA4 subfield (-45%), compared to 
autopsy controls. The variability in binding between 
specimens was similar in TLE and control groups. 
Discussion 
We examined the hypothesis that EAA and IAA neu- 
rotransmitter receptor binding are altered in hippo- 
campal tissue removed from patients with TLE. The 
hippocampal tissue examined in these studies con- 
tained pathological evidence of neuronal loss but not 
advanced mesial temporal sclerosis. Using quantitative 
receptor autoradiography, we found that EAA and 
IAA receptor binding were differentially altered in the 
hippocampus of patients with TLE, compared with au- 
topsy control subjects. The observation that binding 
to IAA (GABA, and benzodiazepine) receptors was 
reduced is consistent with previous observations 141. 
Similarly, the reduction in binding to the PCP receptor 
site located within the excitatory NMDA receptor 
channel was reported in a recent preliminary commu- 
nication {48). The novel observation made in this study 
is that the density of NMDA-type EAA receptor sites 
and glycine modulatory sites was increased in the same 
tissue in which binding to the PCP channel receptor 
was reduced. Thus, we found two possible neurotrans- 
mitter receptor alterations that could contribute to en- 
hanced neuronal excitability: a reduction in IAA recep- 
tor binding and an increase in the ratio of NMDA 
and glycine-type EAA receptors to PCP-type receptors 
within the NMDA receptor-operated channel. Al- 
though this is the first report of an increase in the ratio 
of NMDA receptors to PCP receptors in hippocampus 
from patients with TLE, a similar alteration in the 
NMDA receptorlchannel complex was observed in 
animal experiments, described below [49, 503. This 
change could contribute to enhanced vulnerability of 
the TLE hippocampus to progressive neuronal injury. 
The experimental methods and design of this study 
have some limitations. Both the small number of speci- 
mens and the inherent problems of neuropathological 
variability associated with studies of chronic neurologi- 
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cal brain disorders limit the interpretation of the data. 
Because of the relatively small number of specimens 
per group, the effects of possible confounding variables 
such as the effects of postmortem delay on receptor 
binding in autopsy control specimens or  the effects of 
chronic medication on receptor binding in patients 
with TLE could not be directly determined. Some evi- 
dence suggests that effects of postmortem delay do not 
substantdly alter the results. A previous study with a 
larger number of autopsy specimens demonstrated no 
correlation between the postmortem delay period (0 
to 16 hours) and the density of EAA and IAA receptor 
binding [ 5  l}. Also, the EAA and IAA receptor binding 
changes observed in our study were in opposite direc- 
tions and were regionally selective. This argues against 
a generalized effect of postmortem delay. 
The greater mean age of autopsy control subjects 
compared with patients with TLE may contribute to 
the apparent elevation of receptor binding in TLE pa- 
tients since in a previous study receptor binding densi- 
ties tended to decrease up to 10% per decade in hu- 
mans [5 11. Although these age-related differences may 
contribute to the observed changes, they cannot ex- 
p h n  the entire increase in NMDA and glycine re- 
ceptor binding in patients with TLE (50 to 100% in- 
crease) or  the decreased binding to PCP receptors 
and GABA, or benzodiazepine receptors. 
The effects of medications may be confounding fac- 
tors. Rinsing tissue sections prior to receptor labeling 
should remove perioperative or chronic anticonvulsant 
medications from the tissue of patients with TLE. Only 
1 patient received a medication (morphine) that di- 
rectly alters EAA and IAA receptor binding 1521. It is 
likely, however, that chronic anticonvulsant treatment 
contributed to the changes in receptor binding. Al- 
though none of the patients received anticonvulsant 
compounds whose site of action is at EAA or IAA 
receptors (except one who received primidone in com- 
bination therapy), chronic treatment may indirectly 
cause regulatory changes in these receptors. Although 
there is no experimental evidence to support this idea, 
the effects of chronic anticonvulsant treatment cannot 
be ruled out. 
Another problem was the limited amount of hippo- 
campal tissue avilable from patients with TLE. This 
made it impossible to perform detailed kinetic studies 
to assess whether the changes in equilibrium binding 
represented changes in receptor affinity or alterations 
in receptor numbers. In addition, the severity of re- 
gional neuronal loss in TLE specimens could not be 
reliably assessed in the frozen tissue sections. It is un- 
likely that differences between groups in endogenous 
neurotransmitters and neuromodulations that bind to 
EAA and IAA receptors could account for the ob- 
served changes in receptor binding since the tissue was 
prerinsed prior to receptor labeling under conditions 
that have been demonstrated to minimize potential dif- 
ferences in residual endogenous compounds. How- 
ever, the binding could reflect the presence of very 
adhesive molecules such as polyamines. If this is the 
case, our in vitro observations could reflect physiologi- 
cally significant alterations in the state of receptors in 
living tissue. 
NMDA Recognition Site Binding 
The pattern of NMDA recognition site binding ob- 
served in autopsy control specimens was similar to the 
pattern of binding observed in previous studies of hu- 
man and nonhuman primate hippocampus [ 5  3-55}. 
The regionally selective elevation of NMDA receptor 
binding within the CA1 subfield in stratum lacunosum 
moleculare and stratum pyramidale in TLE specimens 
corresponds to the hippocampal fields that receive the 
majority of EAA neurotransmitter inputs C141. The 
enhanced binding in TLE specimens compared to au- 
topsy controls can be related to several mechanisms or 
combination of mechanisms. The apparent increase in 
NMDA receptor binding in patients with TLE may 
represent a selective loss of these receptors in the au- 
topsy control specimens as a result of postmortem de- 
lay; however, this seems unlikely based on previous 
studies { 5  1, 541. Alternatively, the enhanced binding 
may reflect regulatory changes secondary to altered 
neuronal activity, neuronal injury, adaptive reorganiza- 
tion of neuronal circuits, and/or chronic anticonvulsant 
treatment. Studies in experimental animals demon- 
strated that excitotoxic injury or abnormal functional 
activity in the hippocampus is associated with axonal 
sprouting and synaptic rearrangement [ 56-58}, and 
such synaptic rearrangements appear to occur in the 
hippocampus of patients with TLE C24, 59-61). 
Whether these rearrangements are associated with an 
increase in NMDA receptor binding is not known. We 
found in a series of animal experiments that the nun-  
ber of NMDA receptor (recognition) sites increases 
rapidly by as much as 100% in response to treatment 
with drugs that block the NMDA-operated channel 
C49, 621. 
Previous studies of NMDA receptor (recognition 
site) binding in human brain tissue from patients with 
epilepsy yielded conflicting results. NMDA receptor 
binding was elevated in two preliminary reports of 
NMDA receptor binding in patients with TIE. In one 
study, the maximal amount of ligand bound to the 
NMDA receptor binding was increased 2.5-fold in ho- 
mogenates prepared from the epileptic focus in tempo- 
ral Cortex compared to nonepileptic temporal cortex 
of patients with TLE [63}. In a second study, NMDA 
receptor binding was increased in the entorhind Cortex 
of TLE specimens compared to autopsy controls, as 
determined by quantitative receptor autoradiography 
[64]. Two other preliminary studies suggested that 
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the NMDA recognition site binding is reduced in the 
hippocampus of patients with TLE. Hosford and 
colleagues {48] reported reduced NMDA-sensitive 
[3H]glutamate binding in the CA3 subfield of patients 
with TLE from Ammon’s horn sclerosis. In the second 
study {64), reductions in NMDA receptor binding 
were reported in the CAI, CA3, and CA4 hippocm- 
pal subfields of patients with TLE from Ammon’s horn 
sclerosis. The differences in results may reflect the se- 
verity of the neuropathology in the patients examined. 
In contrast to the extensive neuronal loss in TLE speci- 
mens (i.e., Ammon’s horn sclerosis) examined in the 
studies reporting NMDA receptor loss [48, 641, the 
severity of pathology in our study was not as marked 
and none of our patients had Ammon’s horn sclerosis. 
Three of the 8 TLE specimens in our study contained 
low-grade gliomas. 
Glycine Modtllatoy Site Binding 
Previous studies of EAA receptor binding in TLE did 
not examine strychnine-insensitive {3H)glycine bind- 
ing. The distribution of glycine modulatory site binding 
paralleled the distribution of NMDA recognition site 
binding in the hippocampus of autopsy control speci- 
mens, which is consistent with previous reports of colo- 
calization of these receptors in human brain {65]. The 
regionally selective receptor binding changes observed 
in the hippocampus of patients with TLE paralleled, 
in general, the increases in NMDA recognition site 
binding. One exception was in stratum pyramidale of 
CA1, where only binding to the NMDA recognition 
site was elevated. The coordinate changes in these two 
binding sites are consistent with the idea that these 
two sites are components of the same receptor/channel 
complex (see Fig 1). The results suggest that these two 
sites are simultaneously upregulated in the hippocam- 
pus of patients with TLE despite neuronal injury and 
cell loss. 
Phencyclidine Receptor (Channel Site) Binding 
The topography of C3H}TCP binding in autopsy con- 
trol specimens was similar to the pattern of binding to 
the other two components of the NMDA receptor 
complex (NMDA and glycine receptors), which is con- 
sistent with the idea that these receptors comprise a 
receptor complex (see Fig 1). The distribution of 
C3H]TCP binding was similar to the pattern described 
in previous reports on human hippocampus [66, 67). 
Reduced [?H)TCP binding w a  found in all four hippo- 
campal regions of patients with TLE compared to con- 
trol subjects, in contrast to the more selective regional 
changes found in binding to NMDA and glycine sites. 
The same factors already mentioned (anticonvulsant 
treatment, neuronal cell loss and synaptic reorganiza- 
tion, receptor downregulation, and postmortem autoly- 
sis in control specimens) could have contributed to 
these changes. A previous study suggested that post- 
mortem autolysis does not contribute to the results 
[5  11. Chronic anticonvulsant treatment could have 
contributed to the changes and cannot be ruled out. 
However, none of the anticonvulsants the patients had 
taken are known to have effects at the NMDA recep- 
tor/channel complex. 
Change in the Ratio of NMDA to Phencyclidine 
Binding Sites 
Binding to the PCP receptor site within the NMDA- 
operated ion channel is reduced even though binding 
to the associated NMDA and glycine receptor sites is 
elevated in the same tissue. This change might be re- 
lated either to an increase in NMDA and glycine sites 
not associated with NMDA-operated channels or to an 
apparent change in the ratio of NMDA and glycine 
receptor sites to PCP channel sites per recepcorlchan- 
nel complex {68). There are several experimental pre- 
cedents for a change in the quantitative relationship 
between NMDA receptor sites and PCP channel sites. 
E3HITCP binding is modulated by NMDA and glycine 
receptor activation [69, 701. The effective coupling be- 
tween these receptors may be reduced in patients with 
TLE as has been demonstrated in patients with Alzhei- 
mer’s disease [71-73}, such that the remaining endog- 
enous glutamate and glycine in the tissue sections is 
less effective at increasing E3H)TCP binding. It is also 
possible that multiple genetic forms of NMDA recep- 
tor/channel complexes exist, each with a different ratio 
of NMDA, glycine, and PCP receptors 142). Our data 
could reflect an alteration in the relative numbers of 
these different forms expressed in selected regions of 
TLE hippocampus. 
A third possibility is that the reduction in [3H1TCP 
binding and increased binding to the NMDA recogni- 
tion site reflect a reaction to neuronal injury within 
the hippocampus of patients with TLE and functional 
expression of cryptic NMDA receptors C14, 22-25, 
53-55, 66, 74, 751. Damage to dendrites of principal 
hippocampal neurons could result in a loss of NMDA 
receptorlchannel complexes, reflected in a loss of 
T3H}TCP binding sites. The enhanced NMDA binding 
could reflect functional NMDA receptor upregulation 
secondary to reduction in PCP channel activity. This 
hypothesis is supported by our experimental observa- 
tion that blockade of PCP channels by MK-801 results 
in a prompt increase in NMDA receptors in rodents 
1493. 
Qtlisqgalate-Type Receptor Binding 
The regional distribution of quisqualate receptor bind- 
ing in the hippocampus of control specimens was simi- 
lar to the pattern described previously {53). The mod- 
erate elevation or maintenance of quisqualate receptor 
binding in the hippocampus of patients with TLE de- 
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spite cell loss suggests that these sites are preserved or 
possibly upregulated in TLE. Interpretation of these 
data has the same limitations as that of the data con- 
cerning NMDA receptor binding. These data are con- 
sistent with findings in several preliminary reports of 
increased quisqualate receptor binding in hippocampus 
from patients with epilepsy. In one preliminary study 
of patients with TLE who had Ammon’s horn sclerosis, 
there was significantly increased quisqualate receptor 
binding in stratum moleculare of the dentate gyrus and 
maintained binding in other hippocampal subfields de- 
spite extensive cell loss r48). In a second preliminary 
study, [3H)a-amino-3-hydroxy-5-methyl-4-isoxazole- 
propionic acid (AMPA) binding to a subtype of quis- 
qualate receptors was enhanced in entorhind cortex, 
maintained in stratum moleculare of the dentate gyrus, 
and reduced in CA1, CA3, and CA4 in the context of 
marked cell loss in the hippocampus of patients with 
TLE and with Ammon’s horn sclerosis [64). 
GABA, and Benzodiazepine Receptor Binding 
The regionally selective reductions in GABA, and 
benzodiazepine receptor binding found in patients with 
TLE are consistent with previous reports of reductions 
in GABAergic synaptic markers and selective injury 
and loss of hippocampal neurons 14, 22-25]. Some 
studies demonstrated no alteration in GABAA and 
benzodiazepine receptor binding in patients with TLE 
or other forms of epilepsy 163, 76). It is possible that 
the reduction of GABAA and benzodiazepine binding 
in our study may reflect secondary downregulation re- 
sulting from neuronal injury or chronic anticonvulsant 
therapy. The relative contribution of neuronal loss to 
the decrease in GABA, and benzodiazepine receptor 
binding in specimens from patients with TLE is not 
addressed by this study. It is unclear from this study 
whether the trend for a greater reduction in benzodiaz- 
epine receptor binding than GABAA receptor binding 
in patients with TLE represents differential receptor 
regulation or an artifact of the binding assays. 
Possible ImpEications of Altered Excitatouy 
and Inhibitory Amino Acid Receptor Bindivzg 
The increased NMDA and glycine receptor binding 
and reduced IAA receptor binding observed in TLE 
specimens could predispose the hippocampus to neu- 
ronal hyperexcitability and possibly promote further 
seizures and neuronal injury. NMDA receptor activa- 
tion is involved in burst discharges in hippocampal neu- 
rons [35, 77-80). Sustained bursting may result in ex- 
cessive calcium entry and cytotoxicity [ 11, 12, 81-83). 
Excitotoxic injury in the hippocampus is associated 
with axonal sprouting and synaptic rearrangement [56, 
57) and these processes may be regulated by EAA 
receptor activation [84]. Such synaptic rearrangements 
are likely to occur in TLE [24, 59-61). The increased 
binding to NMDA and glycine modulatory receptors 
in TLE may be related to an adaptive regulatory re- 
sponse to neuronal injury. In experimental paradigms, 
an increase in the ratio of NMDA receptors to PCP 
receptors is associated with an increase in susceptibility 
to neuronai damage from intracerebral injections of 
the excitotoxic glutamate analogue NMDA 1497. If this 
occurs in humans, it could contribute to the develop- 
ment of an epileptogenic focus over time. This could 
be an ongoing, cycling process involving neuronal injury 
and adaptive synaptic reorganization r23, 24, 56-61). 
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